An interventional study of Respiratory rehabilitation in Lung Cancer, sponsored by University Hospital, Lille. Terminated at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Other
The feasibility and impact of respiratory rehabilitation (RR) in patients with advanced or metastatic (EGF-R WT or mutated) non-small cell lung cancer treated with oral targeted therapy including Inhibitors of EGF-R tyrosine kinases (TKI) and ALK inhibitors.
These patients will benefit, at the beginning of the chemotherapy whatever the treatment line, of a respiratory rehabilitation. The respiratory rehabilitation takes place at the patient's home with the HAD's cooperation 3 hours per week, divided into 2 or 3 sessions. There is associated educational, nutritional and psychological support for a total duration of 8 weeks.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 25 is below the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Respiratory rehabilitation
It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
Rate of patients completing the full Respiratory Rehabilitation (8 weeks) at home
Time frame: At 8 weeks
Functional Assessment of Cancer Therapy Lung standardized
measure the quality of life
Time frame: Baseline and 8 weeks
EORTC QLQ C-30 standardized version 3.0
Measure the quality of life
Time frame: Baseline and 8 weeks
Functional capacity
Exercise capacity with the six minutes walk test
Time frame: Baseline and 8 weeks
Respiratory capacity
measured by the spirometry
Time frame: Baseline and 8 weeks
Nutritional Risk Screening score
Nutritional state assessment by albumine and pre albumine dosage
Time frame: Baseline and 8 weeks
Body Mass Index
Time frame: Baseline and 8 weeks
Overall and progression-free survival
Time frame: at 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille